{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:45:52Z","timestamp":1769089552700,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jcv.2026.105913","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:09:27Z","timestamp":1768583367000},"page":"105913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative performance of the Siemens Atellica and Abbott Architect assays for HBsAg quantification in patients with chronic hepatitis B or hepatitis Delta"],"prefix":"10.1016","volume":"182","author":[{"given":"L\u00e9onie","family":"Badot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-No\u00eblle","family":"Hilleret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorra","family":"Guergour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Chirica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Truffot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Morand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eble","family":"Germi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Scholt\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Larrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2026.105913_bib1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, J. Hepatol. 83 (2025) 502\u2013583. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018.","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"10.1016\/j.jcv.2026.105913_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.jcv.2026.105913_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/141.5.590","article-title":"Transmission of the hepatitis B virus-associated delta antigen to chimpanzees","volume":"141","author":"Rizzetto","year":"1980","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2026.105913_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2026.105913_bib5","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1001\/jama.2023.23242","article-title":"Hepatitis D: a review","volume":"330","author":"Negro","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcv.2026.105913_bib6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jcv.2026.105913_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001334","article-title":"Getting to HBV cure-will new biomarkers help?","author":"Feld","year":"2025","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.jcv.2026.105913_bib8","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, EASL Clinical Practice Guidelines on hepatitis delta virus, J. Hepatol. 79 (2023) 433\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.001.","DOI":"10.1016\/j.jhep.2023.05.001"},{"issue":"1","key":"10.1016\/j.jcv.2026.105913_bib9","first-page":"60","article-title":"Treatment endpoints for chronic hepatitis D","volume":"43","author":"Metin","year":"2023","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.jcv.2026.105913_bib10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"HIDT-1 Study Group, Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis","volume":"30","author":"Zachou","year":"2010","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.jcv.2026.105913_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2026.105913_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.jcv.2026.105913_bib13","first-page":"1157","article-title":"Future anti-HDV treatment strategies, including those aimed at HBV functional cure","volume":"43","author":"Tan","year":"2023","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"10.1016\/j.jcv.2026.105913_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2026.105913_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.13734","article-title":"HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response","volume":"44","author":"Niro","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jcv.2026.105913_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/hep.25718","article-title":"A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance","volume":"56","author":"Seto","year":"2012","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.jcv.2026.105913_bib17","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/JCM.06829-11","article-title":"Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis Delta virus from clinical samples in the presence of a heterologous internal-control RNA","volume":"50","author":"Scholtes","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2026.105913_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcv.2014.05.013","article-title":"Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays","volume":"Virol. 60","author":"Burdino","year":"2014","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin."},{"key":"10.1016\/j.jcv.2026.105913_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hep.510270144","article-title":"Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance","volume":"27","author":"Locarnini","year":"1998","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.jcv.2026.105913_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcv.2017.02.001","article-title":"Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples","volume":"89","author":"Thibault","year":"2017","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.jcv.2026.105913_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104553","article-title":"Non-invasive biomarkers for chronic hepatitis B virus infection management","volume":"169","author":"Charre","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jcv.2026.105913_bib22","first-page":"E263","article-title":"Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays","volume":"48","author":"Ozeki","year":"2018","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"10.1016\/j.jcv.2026.105913_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jviromet.2015.11.016","article-title":"The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen","volume":"228","author":"Yang","year":"2016","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2026.105913_bib24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/cid\/ciad506","article-title":"Chronic hepatitis B finite treatment: similar and different concerns with new drug classes","volume":"78","author":"Peters","year":"2024","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.jcv.2026.105913_bib25","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy","volume":"58","author":"Seto","year":"2013","journal-title":"Hepatology"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:58:39Z","timestamp":1769032719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653226000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"alternative-id":["S1386653226000028"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105913","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative performance of the Siemens Atellica and Abbott Architect assays for HBsAg quantification in patients with chronic hepatitis B or hepatitis Delta","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105913"}}